Sartorius Stedim Biotech S.A. (0RG8.L)

367.44 +27.78 (+8.18%) At close: 06:45PM BST

Sartorius Stedim Biotech S.A.

Zone Industrielle Les Paluds
Avenue de Jouques – CS 91051 Cedex
Aubagne 13781
France
33 4 42 84 56 00
https://www.sartorius.com

Sector(s): 
Industry: 
Full-time employees: 11,135

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Rene Faber	CEO & DIrector	410k	N/A	1975
Mr. Rainer Lehmann	CFO & Member of Exec. Board	N/A	N/A	1975
Ms. Petra Muller	Head of Investor Relations	N/A	N/A	N/A
Ms. Petra Kirchhoff	Head of Corp. Communications & IR	N/A	N/A	1969
Olivier Guitard	Head of Controlling BPS	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Corporate governance

Sartorius Stedim Biotech S.A.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.